
    
      The drug being tested in this study is called brigatinib. Brigatinib is being tested in
      patients with ALK-positive NSCLC in order to evaluate efficacy and safety of oral doses of
      brigatinib in Japanese patients with ALK-positive NSCLC.

      The study will enroll approximately 110 participants. Participants will be enrolled in
      non-randomized and opened manner:

      - Brigatinib 90 mg for the first 7 days, followed by Brigatinib 180 mg of Brigatinib tablets,
      once daily in a 28-days cycle.

      All participants will be asked to take tablets of brigatinib once daily with or without food
      throughout the study.

      This multi-center trial will be conducted in Japan. The overall time to participate in this
      study is approximately 53 months. Participants will make multiple visits to the clinic during
      the treatment period, and posttreatment period including a follow-up assessment after last
      dose of study drug.
    
  